KALA BIO, INC.

Profile

Company Names

KALA BIO, INC.
KALA PHARMACEUTICALS, INC.

Addresses

1167 MASSACHUSETTS AVENUE, ARLINGTON, MA 02476

490 ARSENAL WAY, SUITE 120, WATERTOWN, MA 02472

100 BEAVER STREET, SUITE 201, WALTHAM, MA 02453

135 BEAVER STREET, SUITE 309, WALTHAM, MA 02452

135 BEAVER STREET, #309, WALTHAM, MA 02452

MINTZ LEVIN COHN FERRIS GLOVSKY + POPEO, ONE FINANCIAL CENTER, BOSTON, MA 02111

Phone Numbers

781-996-5252
(781) 996-5252
617-542-2241

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS, BIOTECHNOLOGY

Year Incorporated:

2009

State Incorporated:

DELAWARE

Total Amount Raised:

$158,790,560.00

Number of Funding Rounds:

12
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
12
2026-03-03 
$1,753,500.00 
$1,753,500.00 
$0.00 
Equity 
11
2026-01-30 
$2,250,600.00 
$4,200,000.00 
$1,949,400.00 
Equity 
10
2024-12-31 
$10,749,667.00 
$10,749,667.00 
$0.00 
Equity 
9
2024-06-28 
$12,499,192.00 
$12,499,192.00 
$0.00 
Equity 
8
2021-11-15 
$16,122,541.00 
$36,522,541.00 
$20,400,000.00 
Equity 
7
2016-04-06 
$67,921,796.00 
$67,921,796.00 
$0.00 
Equity 
6
2015-08-17 
$6,999,999.00 
$6,999,999.00 
$0.00 
Equity 
5
2014-04-16 
$22,500,000.00 
$22,500,000.00 
$0.00 
Equity 
4
2013-02-14 
$5,750,059.00 
$11,500,118.00 
$5,750,059.00 
Equity 
3
2012-02-29 
$7,243,205.00 
$7,243,205.00 
$0.00 
Equity 
2
2010-10-26 
$3,000,000.00 
$3,000,000.00 
$0.00 
Equity, Debt 
1
2009-12-11 
$2,000,001.00 
$2,000,001.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
TODD 
 
BAZEMORE 
EXECUTIVE OFFICER
CHAIM 
 
BERGER 
DIRECTOR
MARK 
S. 
BLUMENKRANZ 
DIRECTOR
KIM 
 
BRAZZELL 
EXECUTIVE OFFICER
HONGMING 
 
CHEN 
EXECUTIVE OFFICER
YONATAN 
 
COLMAN 
DIRECTOR
PETER 
 
COUROSSI 
EXECUTIVE OFFICER
MARJAN 
 
FARID 
DIRECTOR
BERNARD 
 
GILLY 
DIRECTOR
GREG 
 
GRUNBERG 
DIRECTOR
GREGORY 
 
GRUNBERG 
DIRECTOR
JUSTIN 
 
HANES 
DIRECTOR
MARK 
 
IWICKI 
EXECUTIVE OFFICER, DIRECTOR
DARIUS 
 
KHARABI 
EXECUTIVE OFFICER
ANDREW 
I. 
KOVEN 
DIRECTOR
ANDREW 
L. 
KOVEN 
DIRECTOR
ROBERT 
 
LANGER 
DIRECTOR
MICROCHIPS, INC.   |  ARSENAL MEDICAL, INC.   |  ALSERES PHARMACEUTICALS INC /DE   |  ECHO THERAPEUTICS, INC.   |  MICELL TECHNOLOGIES INC   |  CERULEAN PHARMA INC.   |  HUMACYTE INC   |  COMBINENT BIOMEDICAL SYSTEMS, INC.   |  TARIS BIOMEDICAL INC   |  KALA PHARMACEUTICALS, INC.   |  FIBROCELL SCIENCE, INC.   |  PREDICTIVE BIOSCIENCES, INC   |  SEVENTH SENSE BIOSYSTEMS, INC.   |  T2 BIOSYSTEMS, INC.   |  SEMPRUS BIOSCIENCES CORP   |  LIQUIDX, INC.   |  ARSENAL VASCULAR, INC.   |  ARSENAL MEDICAL, INC.   |  SELECTA BIOSCIENCES INC   |  STEMNION, INC.   |  480 BIOMEDICAL, INC.   |  LIVING PROOF INC   |  DX BIOSCIENCES, INC.   |  MODERNA LLC   |  HUMACYTE, INC   |  XTUIT PHARMACEUTICALS, INC.   |  SQZ BIOTECHNOLOGIES CO   |  NOVEOME BIOTHERAPEUTICS, INC.   |  LYNDRA, INC.   |  MODERNA THERAPEUTICS, INC.   |  VERSEAU THERAPEUTICS, INC.   |  FREQUENCY THERAPEUTICS, INC.   |  SUONO BIO, INC.   |  COMBINED THERAPEUTICS, INC.   |  HUMACYTE, INC.   |  SEER BIOSCIENCES, INC.   |  LANDSDOWNE LABS, LLC   |  LIKEMINDS, INC./DE   |  TARVEDA THERAPEUTICS, INC.   |  LUMINOPIA, INC.   |  LYRA THERAPEUTICS, INC.   |  ABPRO CORP   |  GLYMPSE BIO, INC.   |  EPIBONE, INC.   |  TEAL BIO, INC.   |  ZWI THERAPEUTICS, INC.   |  LYNDRA THERAPEUTICS, INC.   |  KENDALL CAPITAL PARTNERS I, L.P.   |  BILAYER THERAPEUTICS, INC.   |  XENTER, INC.   |  VIVTEX CORP   |  SYNTIS BIO, INC.   |  OMNIPULSE BIOSCIENCES, INC.
AVI 
 
MINKOWITZ 
EXECUTIVE OFFICER, DIRECTOR
C. 
DANIEL 
MYERS 
DIRECTOR
GREGORY 
D. 
PERRY 
DIRECTOR
GUILLAUME 
 
PFEFER 
EXECUTIVE OFFICER, DIRECTOR
KEVIN 
 
POJASEK 
EXECUTIVE OFFICER
HILLEL 
 
POSEN 
DIRECTOR
MARY 
 
REUMUTH 
EXECUTIVE OFFICER
HOWARD 
B. 
ROSEN 
DIRECTOR
ERIC 
L. 
TRACHTENBERG 
EXECUTIVE OFFICER
KAREN 
 
WAGNER 
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2026-03-03 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2026-01-30 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2024-12-31 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2024-06-28 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2021-11-15 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2016-04-06 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2015-08-17 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2014-04-16 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2013-02-14 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-02-29 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2010-10-26 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2009-12-11 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
FM GLOBAL MARKETS INC.